Pruritus Therapeutics Market (2026 - 2033)

Pruritus Therapeutics Market Summary

The global pruritus therapeutics market size was valued at USD 9.3 billion in 2025 and is projected to grow from USD 9.7 billion in 2026 to USD 13.4 billion by 2033, at a CAGR of 4.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 38.6% in 2025. Skin conditions such as acne, eczema, psoriasis, and skin cancer often have pruritus as a primary symptom, increasing the demand for treatments.

This trend is expected to continue, with approximately 200,340 new cases of melanoma estimated to be diagnosed in the U.S. in 2024, as reported by the AIM at Melanoma Foundation. As a result, market players are investing in research and development to create innovative therapies and launch new medications to cater to the growing demand.

A 2023 Oxford University Press analysis forecasts a 4% increase in UK chronic kidney disease prevalence by 2032, underscoring the necessity for innovative treatments to address this growing healthcare concern and mitigate its economic implications. The growing demand for pruritus therapeutics is also driven by the increasing awareness of the condition and the availability of new treatments. For instance, in October 2024, Alvotech and Teva announced FDA approval for a new intravenous presentation of SELARSDI (ustekinumab-aekn) in the U.S., expanding indications to include Crohn’s disease and ulcerative colitis.

Patients are increasingly turning to over-the-counter (OTC) topical medicines due to their low cost, similar effectiveness, and convenient availability. This trend is expected to continue, with market players investing in the development of OTC products to cater to the growing demand. Furthermore, the growing aging population and advancements in drug formulations also contribute to the market’s expansion. As the population ages, the incidence of pruritus is expected to increase, driving the demand for effective treatments.

Key market players, such as Pfizer Inc., are investing in R&D to create innovative therapies and launch new medications. For instance, in March 2024, Amgen presented significant findings on Otezla (apremilast) at the AAD Annual Meeting in the U.S., showcasing its efficacy in treating moderate to severe plaque psoriasis in pediatric populations. The launch of new products and the expansion of existing product portfolios are expected to drive industry growth in the coming years. As the market continues to evolve, market players are expected to focus on developing innovative and effective treatments to cater to the growing demand for pruritus therapeutics.

Market Dynamics

The pruritus therapeutics market is driven by the increasing prevalence of chronic pruritus associated with dermatological, systemic, neurological, and renal disorders. Rising awareness of chronic itch as a condition requiring long-term medical management has supported earlier diagnosis and timely treatment. The market includes topical therapies, systemic drugs, biologics, and targeted therapies designed to address different causes and severity levels of pruritus. The availability of therapies targeting specific inflammatory pathways has expanded treatment options, particularly for patients with moderate to severe disease. In addition, ongoing clinical research continues to support the development of therapies with improved safety and efficacy profiles. Hospitals, specialty clinics, retail pharmacies, and online pharmacies play an important role in improving patient access to treatment across many regions. However, limited diagnosis rates in some patient groups, unequal access to advanced therapies, differences in reimbursement policies, and the high cost of newer biologic treatments continue to restrict broader market growth, particularly in low- and middle-income countries.

Analyst Perspective

The pruritus therapeutics market is shifting from conventional symptom-based treatment toward targeted therapies that address the underlying inflammatory and immune pathways responsible for chronic itch. The market is becoming more focused on companies with established dermatology and immunology portfolios, supported by continued investment in biologics and novel small-molecule therapies. Galderma has strengthened its position through the expansion of Nemluvio (nemolizumab) across pruritic skin disorders, while Sanofi and Regeneron continue to expand the clinical use of Dupixent (dupilumab) in inflammatory diseases associated with chronic pruritus. In addition, Eli Lilly, AbbVie, Pfizer, and Incyte are advancing targeted therapies and expanding approved indications, contributing to broader treatment options for patients with chronic pruritus across multiple underlying diseases.

Disease Insights

Based on disease, the atopic dermatitis segment led the market with the largest revenue share of 50.8% in 2025. Eczema or atopic dermatitis is one of the most common chronic skin diseases, often beginning in early childhood. Skin conditions may be associated with allergic rhinitis, asthma, and food allergies. Certain foods such as citrus fruits, eggs, tomatoes & milk can also cause eczema in young children. According to National Eczema Association, approximately 9.6 million U.S. children under the age of 18 have atopic dermatitis, and one-third have moderate to severe disease.

Allergic contact dermatitis is expected to grow at the fastest CAGR of 4.8% over the forecast period.The rising global prevalence of allergic contact dermatitis is a primary driver of market growth. Moreover, increasing allergies and skin sensitivities, exacerbated by environmental pollution, particularly in urban areas, contribute to the heightened demand for effective treatments. This segment is the fastest-growing within the Indian pruritus therapeutics market, reflecting strong market potential and an urgent need for targeted therapeutic interventions.

Product Insights

Based on product, the antihistamines segment led the market with the largest revenue share of 61.4% in 2025. Corticosteroids are anti-inflammatory drugs and are used to provide comfort by reducing inflammation. A few corticosteroids include cortisone, dexamethasone, prednisolone, and hydrocortisone. Moreover, corticosteroids lessen allergic responses, itching, swelling, and redness. They are applied to numerous types of pruritus. Due to their wide range of uses, corticosteroids are common pruritus treatments, which accounts for their market domination.

Antihistamines are expected to register significant growth over the forecast period, driven by the increasing prevalence of allergies worldwide, leading to a high demand for relief from symptoms such as itching and hives. Antihistamines are widely used as a first-line treatment for pruritus, allergic contact dermatitis, and atopic dermatitis, offering an effective and convenient therapeutic option.

Distribution Channel Insights

Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 58.8% in 2025. Healthcare institutions are increasingly prioritizing comprehensive medication management to enhance patient care. Hospital pharmacies improve adherence to prescribed therapies by ensuring accessibility and convenience. The integration of pharmacy services allows for personalized medication counseling, while customized formulations address the needs of patients with severe pruritus. Collaborative efforts between healthcare providers and pharmacists further enhance treatment outcomes in managing pruritus.

Online pharmacies are projected to grow at the fastest CAGR of 5.9% over the forecast period, added by their convenience, offering home delivery services that appeal to tech-savvy individuals and those with mobility challenges. Furthermore, the COVID-19 pandemic has accelerated the adoption of online pharmacies, reflecting a growing consumer preference for digital healthcare solutions. The rise of digitalization and e-commerce trends enhances their growth, supported by competitive pricing compared to traditional pharmacies.

Regional Insights

North America dominated the pruritus therapeutics market with the largest revenue share of 38.6% in 2025. North America’s well-established healthcare infrastructure provides a robust platform for affordable and accessible treatments, driving demand for pruritus treatments. A high prevalence of dermatological conditions and substantial healthcare expenditure contribute to the region’s market growth. Key market players, led by AbbVie Inc., Amgen Inc., and Pfizer Inc., are developing innovative therapeutic options, including biologics and targeted treatments. Government initiatives, favorable policies, and R&D investments further propel market expansion.

U.S. Pruritus Therapeutics Market Trends

The pruritus therapeutics market in the U.S. held the largest share in the North America region in 2025. The introduction of new products and the presence of favorable government initiatives are some key factors attributing to its large share. Furthermore, the growing prevalence of target diseases and the presence of pruritus-inducing climatic conditions in the region are expected to drive market growth during the forecast period.

Europe Pruritus Therapeutics Market Trends

Europe pruritus therapeutics market held substantial market share in 2024. The growing prevalence of pruritus-related conditions, including atopic dermatitis and psoriasis, is fueling market growth. Key players are prioritizing investments in research and development to innovate pruritus therapies, alongside launching new medications and strengthening their product pipelines. Moreover, the robust healthcare infrastructure facilitates affordable and accessible treatment options, further contributing to market expansion.

The pruritus therapeutics market in Germany is expected to grow in the forecast period, driven by factors such as the rising incidence of skin disorders, such as eczema and psoriasis, which affect 5%-10% of the population, as reported by the British Association of Dermatologists. The nation’s robust healthcare system ensures access to necessary treatments. Moreover, significant investments in R&D by pharmaceutical companies foster the development of innovative therapies. A 2024 study Bertelsmann Foundation study showed that the country houses approximately 22% of those aged 65 and older. This aging demographic further amplifies the demand for pruritus management solutions, supported by government initiatives and awareness campaigns.

Asia Pacific Pruritus Therapeutics Market Trends

Asia Pacific pruritus therapeutics market is expected to register the fastest CAGR of 6.1% in the forecast period. A recent study at the 2023 Skin of Color Update Conference revealed distinct differences in the presentation, genetics, and treatment responses of inflammatory skin conditions among Asians, supported by the findings of a 2023 study by the NCBI. According to the Journal of the European Academy of Dermatology and Venereology, common skin disorders recorded in Singapore include eczema, hives, and acne, similar to other countries in the region. Favorable government initiatives in Japan and Australia are driving growth opportunities. For instance, in September 2024, Kyowa Kirin announced positive top-line results from the Phase 3 ROCKET HORIZON trial in Japan, demonstrating rocatinlimab’s efficacy for adults with moderate to severe atopic dermatitis.

India pruritus therapeutics market is expected to grow at the fastest rate over the forecast period in the Asia Pacific market. Increasing prevalence of dermatological disorders such as eczema and psoriasis fuels demand for therapeutics. India’s large population, coupled with growing awareness and government initiatives, significantly contributes to market growth, presenting opportunities for therapeutic development.

Key Pruritus Therapeutics Company Insights

Some key companies operating in the market include AbbVie Inc.; Amgen, Inc.; Astellas Pharma Inc.; and Bristol-Myers Squibb; among others. The market hosts numerous global and regional companies competing through collaborations, acquisitions, and strategic initiatives such as clinical trials and R&D investments.

• AbbVie is a significant competitor in the pruritus therapeutics market, emphasizing immunology research and developing innovative treatments, including the approved RINVOQ (upadacitinib) for moderate to severe atopic dermatitis. The company is also conducting clinical trials for various immune-mediated disorders.

• Bristol-Myers Squibb addresses pruritus treatment through cholestyramine for cholestatic pruritus, the development of BMS-981164 targeting IL-31, topical corticosteroids for mild to moderate rashes, and Sotyktu for moderate-to-severe psoriasis, alongside extensive immunology research.

Key Pruritus Therapeutics Companies:

The following key companies have been profiled for this study on the pruritus therapeutics market.

• AbbVie Inc.

• Amgen, Inc.

• Astellas Pharma Inc.

• Bristol-Myers Squibb

• Cara Therapeutics

• GSK plc

• Novartis AG

• Pfizer Inc.

• Sanofi

• Teva Pharmaceutical Industries Ltd

Competitive Benchmarking

Recent Developments

• In November 2024, the FDA accepted the sBLA for Dupixent (dupilumab) to treat chronic spontaneous urticaria in the U.S., with a decision expected by April 18, 2025, featuring pivotal data on efficacy.

• In January 2024, Glenmark and Pfizer partnered to launch abrocitinib in India, marking it as the first oral advanced systemic treatment for moderate-to-severe atopic dermatitis, enhancing patient quality of life.

• In March 2024, AbbVie and Allergan Aesthetics showcased 29 abstracts at the American Academy of Dermatology Annual Meeting in San Diego, highlighting advancements in dermatology and aesthetics portfolios.

Pruritus Therapeutics Market Report Scope

Global Pruritus Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pruritus therapeutics market report based on disease, product, distribution channel, and region:

• Disease Outlook (Revenue, USD Million, 2021 - 2033)

  • Atopic Dermatitis

  • Allergic Contact Dermatitis

  • Urticaria

  • Others

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Corticosteroids

  • Antihistamines

  • Local Anesthetics

  • Counterirritants

  • Immunosuppressant

  • Calcineurin Inhibitors

  • Others

• Distribution Chanel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies 

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The pruritus therapeutics market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each pruritus therapeutics segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

The study incorporated a combination of primary and secondary research methodologies to evaluate the global pruritus therapeutics market. Secondary research involved the review of company annual reports, investor presentations, regulatory filings, product labels, clinical trial registries, scientific publications, treatment guidelines, epidemiology studies, healthcare databases, industry journals, and publicly available information from pharmaceutical companies, regulatory authorities, and healthcare organizations. Primary research included interviews and discussions with dermatologists, allergists, nephrologists, hepatologists, pharmaceutical manufacturers, researchers, business development executives, distributors, and key opinion leaders to validate disease prevalence, treatment patterns, product adoption, prescribing trends, competitive developments, pricing, reimbursement, and future market opportunities. The findings from both research approaches were integrated to estimate the market size, assess segment-level trends, and validate regional and country-level forecasts for the pruritus therapeutics market.

Delivered Customizations

This report has been delivered with the following In-depth customizations